
Dr. Reddy's Laboratories Ltd: stock overview
Price
$14.89
November 20, 2026Market cap $12.4B
What Ploutos Investor adds for Dr. Reddy's Laboratories
Part of Ploutos Investor, €9.99 a month
- The full history: 11 fiscal years, from FY2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
Dr. Reddy's Laboratories had revenue of $3.6B in the fiscal year to March 31, 2026 and net income of $457M, a net margin of 12.8%. Revenue grew by 12.1% a year on average over the last 5 years. At $14.89 the shares trade at a P/E of 27.2, against a median of 18.3 over the last 5 fiscal years. It has net debt of $597M. It pays a dividend yielding 0.57%.
From its SEC filings (latest fiscal year to March 31, 2026) and the price of November 20, 2026.
Its SEC filings- Market cap
- $12.4B
- 835M shares
- P/E
- 27.2
- Today27.2Median18.3
- Revenue, fiscal year
- $3.6B
- +12.1% a year over 5 years
- Net margin
- 12.8%
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+9.7% a year over 2 years
Fiscal years in figures
RDY's revenue, profit, cash flow and dividend with each year-end price, from FY2016 to FY2023, 8 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $11.6B
- $12.4B
- Enterprise value
- $13.0B
- P/E 3-year median: 18.3
- 27.2
- EV / EBIT
- 24.2
- EV / Revenue
- 3.6
- P/B 3-year median: 2.9
- 3.1
- FCF yield 3-year median: 2.9%
- 2.9%
- Earnings yield 3-year median: 5.5%
- 3.7%
Profitability
- Gross margin
- 52.8%
- Operating margin
- 15.0%
- Net margin 3-year median: 17.4%
- 12.8%
- ROIC
- 8.8%
- ROIC, 5-year average
- 14.2%
- ROE, fiscal year
- 11.3%
Growth
- Revenue, yearly change
- +3.2%
- EPS, yearly change
- -24.1%
- FCF, yearly change
- +76.6%
- Revenue, average a year
- +12.1%
- EPS, average a year
- +19.9%
The yearly change compares FY2026 with FY2025.
Balance sheet
- Cash
- $164M
- Total debt
- $760M
- Net debt
- $597M
- Net debt / EBITDA
- 0.8x
- Interest cover
- –
- Current ratio
- –
Balance sheet of March 31, 2026.
Returns to shareholders
- Dividend yield 3-year median: 0.7%
- 0.57%
- Buybacks
- –
- Total returned
- 0.57%
- Shares, yearly change
- +0.2%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- DR REDDYS LABORATORIES LTD
- CIK
- 1135951
- Exchange
- NYSE
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- March 31
- Latest annual report
- March 31, 2026
- Reporting currency
- INR
- Shares
- 835M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with RDY
- JNJJohnson & Johnson+0,00%Compare with RDY
- ABBVAbbVie+0,00%Compare with RDY
- UNHUnitedHealth+0,00%Compare with RDY
- MRKMerck & Company+0,00%Compare with RDY
- AMGNAmgen+0,00%Compare with RDY
- TMOThermo Fisher Scientific+0,00%Compare with RDY
- ABTAbbott Laboratories+0,00%Compare with RDY
The full analysis
What do Dr. Reddy's Laboratories's filings show?
These are Dr. Reddy's Laboratories's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is RDY's market cap?
Dr. Reddy's Laboratories Ltd's market cap is $12.4B, at a price of $14.89 on November 20, 2026 and 835M shares.
What is RDY's P/E?
RDY's P/E is 27.2, on earnings per share of $0.55 in the fiscal year to March 31, 2026. The median over the last 5 fiscal years was 18.3.
How much revenue does RDY have?
Dr. Reddy's Laboratories had revenue of $3.6B in the fiscal year to March 31, 2026. Over the last 5 years it changed by +12.1% a year on average.
Does RDY pay a dividend?
Yes. Dr. Reddy's Laboratories paid $0.09 per share over the last 12 months, a yield of 0.57% at today's price. All the figures are in the Dividend section.
Where do the figures come from?
From Dr. Reddy's Laboratories Ltd's SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.